Lantern Pharma (LTRN) Set to Post Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. During the same period last year, the firm earned ($0.44) EPS. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Performance

Shares of LTRN opened at $3.27 on Wednesday. Lantern Pharma has a 1 year low of $2.74 and a 1 year high of $11.99. The stock has a market capitalization of $35.22 million, a P/E ratio of -1.98 and a beta of 1.58. The company’s fifty day moving average is $3.66 and its two-hundred day moving average is $4.55.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.